Drug
INT230-6
INT230-6 is a pharmaceutical drug with 4 clinical trials. Currently 2 active trials ongoing. Historical success rate of 100.0%.
Total Trials
4
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 1 completed trials
Completion Rate
100%(1/1)
Active Trials
2(50%)
Results Posted
100%(1 trials)
Phase Distribution
Ph phase_3
1
25%
Ph phase_1
1
25%
Ph phase_2
2
50%
Phase Distribution
1
Early Stage
2
Mid Stage
1
Late Stage
Phase Distribution4 total trials
Phase 1Safety & dosage
1(25.0%)
Phase 2Efficacy & side effects
2(50.0%)
Phase 3Large-scale testing
1(25.0%)
Highest Phase Reached
Phase 3Trial Status & Enrollment
Completion Rate
100.0%
1 of 1 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
2
trials recruiting
Total Trials
4
all time
Status Distribution
Active(2)
Completed(1)
Other(1)
Detailed Status
Active, not recruiting1
unknown1
Completed1
Recruiting1
Development Timeline
Analytics
Development Status
Total Trials
4
Active
2
Success Rate
100.0%
Most Advanced
Phase 3
Trials by Phase
Phase 11 (25.0%)
Phase 22 (50.0%)
Phase 31 (25.0%)
Trials by Status
active_not_recruiting125%
unknown125%
completed125%
recruiting125%
Recent Activity
2 active trials
Showing 4 of 4
recruitingphase_2
Intratumoral INT230-6 Followed by Neoadjuvant Immuno-chemotherapy in Patients With Early TNBC. INVINCIBLE-4-SAKK
NCT06358573
active_not_recruitingphase_3
A Study to Investigate Efficacy & Safety of Intratumoral INT230-6 Compared to US Standard of Care in Adults With Soft Tissue Sarcomas (INVINCIBLE-3)
NCT06263231
completedphase_1
A Phase 1/2 Safety Study of Intratumorally Dosed INT230-6
NCT03058289
unknownphase_2
INVINCIBLE TRIAL: Intratumoral INT230-6 in Breast Cancer
NCT04781725
Clinical Trials (4)
Showing 4 of 4 trials
NCT06358573Phase 2
Intratumoral INT230-6 Followed by Neoadjuvant Immuno-chemotherapy in Patients With Early TNBC. INVINCIBLE-4-SAKK
NCT06263231Phase 3
A Study to Investigate Efficacy & Safety of Intratumoral INT230-6 Compared to US Standard of Care in Adults With Soft Tissue Sarcomas (INVINCIBLE-3)
NCT03058289Phase 1
A Phase 1/2 Safety Study of Intratumorally Dosed INT230-6
NCT04781725Phase 2
INVINCIBLE TRIAL: Intratumoral INT230-6 in Breast Cancer
All 4 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 4